RA'ANANA, Israel, Sept. 24, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW), ("Inspira Technologies", "Inspira", or the "Company") a breakthrough medical technology company, is poised to make a significant impact at the 34th Annual Extracorporeal Life Support Organization (ELSO) Conference in Detroit, Michigan, on the 29th to the 30th of September 2024. The Company will be presenting its latest and future technologies, underscoring its commitment to innovation and excellence ...

Inspira Technologies OXY B.H.N. Ltd. (IINN) has secured an additional U.S. Patent approval for the VORTX orbiting blood oxygenation delivery system, a fundamental technology of the INSPIRA ART (Augmented Respiration Technology) device. With this addition, the total number of claims deemed novel relating to the core technology of the device comes to 32. The latest development advances blood oxygenation technologies, marking another crucial milestone for the company and underscoring the core technological cap ...

To date, a combined total of 32 claims have been deemed novel for the core technology of the INSPIRA™ ART deviceTargeting treatment for 20 million ICU patients with respiratory failure annually, with many relying on mechanical ventilators, in a $19 billion industryRA'ANANA, Israel, Sept. 13, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company targeting to supersede mechanical ventilator ...

Inspira Technologies OXY B.H.N. Ltd. (IINN) recently announced plans to report clinical results for its new HYLA blood sensor in open-heart surgery patients. Since the medical industry is highly interested in the HYLA blood sensor, these clinical results should be on par with Inspira's long-term growth plans.About Inspira’s HYLA Blood SensorHYLA blood sensor is an advanced tubing clip-on sensor designed to monitor a patient’s state in real-time by continuously measuring vital blood parameters. The clip-on H ...

The clip-on HYLA™ blood sensor, designed to alert physicians of immediate signs of changes in a patient's clinical condition without the need for intermittent actual blood samples, targets a potential $2.5 billion Point of Care testing and Arterial Blood Gas (ABG) analyzer market.RA'ANANA, Israel, Aug. 28, 2024  /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, has announced plans to report clinic ...

RA'ANANA, Israel, Aug. 22, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN)  (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, today announces the U.S. Food and Drug Administration ("FDA") listing of its medical cart (INSPIRA™ CART) which has been custom designed for use with the INSPIRA™ ART100 system. With this dynamic combination of cutting-edge technology and operational efficiency, Inspira aims to streamline healthcare delivery in a va ...

RA'ANANA, Israel, Aug. 13, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira," "Inspira Technologies," or the "Company"), a trailblazer in life-support technology, today announced that it was approached by a leading medical technology company in the industry, to evaluate the operation of its proprietary key product in combination with the INSPIRA™ ART100 system. The evaluation was conducted by Inspira researchers. The test results exceeded 100% of the standar ...

Inspira's innovation targets life-saving intervention for patients with cardiac arrest, of which there are approximately 550,000 annual cardiac arrest events in the U.S., including 350,000 outside hospitals, where the survival rate is less than 10%.The INSPIRA Cardi-ART provides the Company a new market opportunity to target the $39.8 billion global cardiac arrest market.*RA'ANANA, Israel, July 30, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company", "Insp ...

Approval follows the FDA clearance announced on May 28, 2024 RA'ANANA, Israel, July 11, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, is excited to announce the receipt of the Israeli Ministry of Health's medical devices and accessories ("AMAR") approval for the INSPIRA™ ART100, an Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass system. This is a pivotal milestone in Inspira's ...

Inspira Technologies OXY B.H.N. Ltd. (IINN) disclosed a new business plan with targets for next-generation technologies over a company conference call today. IINN primarily talked about the progress with its core blood oxygenation technology, the INSPIRA ART (Gen 2). Inspira plans to strengthen its position in the mechanical ventilation market with its flagship INSPIRA ART (Gen 2) device. The company is also planning to deploy INSPIRA ART100, its cardiopulmonary support device, in the United States and abro ...